Clin Endosc.  2021 Jul;54(4):494-498. 10.5946/ce.2020.073.

Photodynamic Therapy for Esophageal Cancer

• Inoue T
• Ishihara R

• KMID: 2518851
• DOI: http://doi.org/10.5946/ce.2020.073

Abstract

Photodynamic therapy, a curative local treatment for esophageal squamous cell carcinoma, involves a photosensitizing drug (photosensitizer) with affinity for tumors and a photodynamic reaction triggered by laser light. Previously, photodynamic therapy was used to treat superficial esophageal squamous cell carcinoma judged to be difficult to undergo endoscopic resection. Recently, photodynamic therapy has mainly been performed for local failure after chemoradiotherapy. Although surgery is the most promising treatment for local failure after chemoradiotherapy, its morbidity and mortality rates are high. Endoscopic resection is feasible for local failure after chemoradiotherapy but requires advanced skills, and its indication is limited to within the submucosal layer by depth. Photodynamic therapy is less invasive than surgery and has a wider indication than endoscopic resection. Porfimer sodium (a first-generation photosensitizer) causes a high frequency of side effects related to photosensitivity and requires the long-term sunshade period. Talaporfin (a second-generation photosensitizer) requires a much shorter sun-shade period than porfimer sodium. Photodynamic therapy will profoundly change treatment strategies for local failure after chemoradiotherapy.

Keyword

Endoscopic mucosal resection; Endoscopic submucosal dissection; Endoscopic treatment; Esophageal squamous cell carcinoma; Photodynamic therapy

Figure

• 

  Fig. 1. A case of local failure after chemoradiotherapy (CRT) effectively treated with photodynamic therapy (PDT). (A) A local failure lesion after CRT limited to within T2. (B) PDT was performed. (C) Esophageal stricture occurred 3 months after PDT. (D) The stricture was treated with endoscopic balloon dilation. (E) A scar 18 months after PDT without evidence of recurrence.

Reference

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–E386.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108.

3. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998; 90:889–905.

4. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg. 1996; 14:323–328.

5. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978; 38:2628–2635.

6. Yano T, Muto M, Minashi K, et al. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer. 2012; 131:1228–1234.

7. Kato H, Furukawa K, Sato M, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003; 42:103–111.

8. Yano T, Kasai H, Horimatsu T, et al. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget. 2017; 8:22135–22144.

9. Yoshida K, Suzuki S, Mimura S, et al. [Photodynamic therapy for superficial esophageal cancer: a phase III study using PHE and excimer dye laser]. Gan To Kagaku Ryoho. 1993; 20:2063–2066.

10. Nakamura T, Fukui H, Shirakawa K, Fujii Y, Fujimori T, Terano A. Photodynamic therapy of superficial esophageal cancer with a transparent hood. Gastrointest Endosc. 2004; 60:120–124.

11. Tanaka T, Matono S, Nagano T, et al. Photodynamic therapy for large superficial squamous cell carcinoma of the esophagus. Gastrointest Endosc. 2011; 73:1–6.

12. Inoue H, Endo M. Endoscopic esophageal mucosal resection using a transparent tube. Surg Endosc. 1990; 4:198–201.

13. Inoue H, Endo M, Takeshita K, et al. Endoscopic resection of early-stage esophageal cancer. Surg Endosc. 1991; 5:59–62.

14. Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005; 3(7 Suppl 1):S67–S70.

15. Ono S, Fujishiro M, Niimi K, et al. Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc. 2009; 70:860–866.

16. Ishihara R, Arima M, Iizuka T, et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc. 2020; 32:452–493.

17. Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009; 39:638–643.

18. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011; 81:684–690.

19. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281:1623–1627.

20. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002; 20:1167–1174.

21. Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002; 123:175–183.

22. Swisher SG, Deford L, Merriman KW, et al. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000; 119:1126–1132.

23. Onozawa M, Nihei K, Ishikura S, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 2009; 92:266–269.

24. Hatogai K, Yano T, Kojima T, et al. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016; 83:1130–1139.e3.

25. Yano T, Muto M, Hattori S, et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008; 40:717–721.

26. Kato H, Horai T, Furuse K, et al. Photodynamic therapy for cancers: a clinical trial of porfimer sodium in Japan. Jpn J Cancer Res. 1993; 84:1209–1214.

27. Kessel D. Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. J Photochem Photobiol B. 1997; 39:81–83.

28. Minamide T, Yoda Y, Hori K, et al. Advantages of salvage photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Surg Endosc. 2020; 34:899–906.